HP
BMRN icon

Havemeyer Place’s BioMarin Pharmaceuticals BMRN Stock Holding History

Havemeyer Place’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Buy
+33,490
New +$1.83M 0.19% 184
2026
Q1 		– Sell
-29,329
Closed -$1.74M – 531
2025
Q4 		$1.74M Buy
+29,329
New +$1.6M 0.34% 82

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Havemeyer Place's BMRN Position: Q2 2026 in Review

Havemeyer Place opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 33,490 shares worth $1.92M. The stake represents 0.19% of the portfolio and ranks #184 among its holdings. This is a return to the name: Havemeyer Place previously reported a position in BMRN as recently as Q4 2025.

Havemeyer Place first reported a position in BMRN in Q4 2025 and has held it in 2 quarters since. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Havemeyer Place held 33,490 shares of BioMarin Pharmaceuticals worth $1.92M as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Havemeyer Place position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.19% of Havemeyer Place's portfolio in Q2 2026, its #184 holding.
  • Havemeyer Place first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Havemeyer Place's 13F filing for Q2 2026, filed 13 Aug 2026.